Targeting JAK kinase in solid tumors: emerging opportunities and challenges (Q38485889)

3 September 2017

1 reference

title

Targeting JAK kinase in solid tumors: emerging opportunities and challenges (English)

1 reference

3 September 2017

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25982279%20AND%20SRC:MED&resulttype=core&format=json

11 June 2020

Matthias Ernst

series ordinal

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25982279%20AND%20SRC:MED&resulttype=core&format=json

11 June 2020

author name string

M Buchert

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25982279%20AND%20SRC:MED&resulttype=core&format=json

11 June 2020

language of work or name

English

0 references

publication date

18 May 2015

1 reference

3 September 2017

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25982279%20AND%20SRC:MED&resulttype=core&format=json

11 June 2020

volume

35

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25982279%20AND%20SRC:MED&resulttype=core&format=json

11 June 2020

issue

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25982279%20AND%20SRC:MED&resulttype=core&format=json

11 June 2020

page(s)

939-951

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25982279%20AND%20SRC:MED&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.1038/onc.2015.150

11 June 2020

exact match

0 references

cites work

Molecular cloning of L-JAK, a Janus family protein-tyrosine kinase expressed in natural killer cells and activated leukocytes

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.150

Two novel protein-tyrosine kinases, each with a second phosphotransferase-related catalytic domain, define a new class of protein kinase

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.150

Janus kinases in immune cell signaling

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.150

Widespread occurrence of the JAK2 V617F mutation in chronic myeloproliferative disorders

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.150

A gain-of-function mutation of JAK2 in myeloproliferative disorders

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.150

The JAK2 V617F activating tyrosine kinase mutation is an infrequent event in both "atypical" myeloproliferative disorders and myelodysplastic syndromes

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.150

Activating alleles of JAK3 in acute megakaryoblastic leukemia

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.150

Hallmarks of Cancer: The Next Generation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.150

The IL-6 feed-forward loop: a driver of tumorigenesis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.150

IL-6 involvement in epithelial cancers

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.150

gp130 at the nexus of inflammation, autoimmunity, and cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.150

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.150

Interleukin-11 is the dominant IL-6 family cytokine during gastrointestinal tumorigenesis and can be targeted therapeutically

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.150

Autocrine production of IL-11 mediates tumorigenicity in hypoxic cancer cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.150

Dependency of colorectal cancer on a TGF-β-driven program in stromal cells for metastasis initiation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.150

Regulation of the IL-23 and IL-12 balance by Stat3 signaling in the tumor microenvironment

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.150

Adenoma-linked barrier defects and microbial products drive IL-23/IL-17-mediated tumour growth

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.150

Impaired development of human Th1 cells in patients with deficient expression of STAT4.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.150

JAK-STAT signaling: from interferons to cytokines

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.150

IL-23 drives a pathogenic T cell population that induces autoimmune inflammation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.150

Understanding and exploiting the endogenous interleukin-10/STAT3-mediated anti-inflammatory response

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.150

Selective expression of interleukin 10, interferon gamma, and granulocyte-macrophage colony-stimulating factor in ovarian cancer biopsies

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.150

High incidence of interleukin 10 mRNA but not interleukin 2 mRNA detected in human breast tumours

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.150

Significance of −1082A/G polymorphism of IL10 gene for progression of colorectal cancer and IL-10 expression

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.150

IL-10 directly activates and expands tumor-resident CD8(+) T cells without de novo infiltration from secondary lymphoid organs

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.150

IL-10 elicits IFNγ-dependent tumor immune surveillance.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.150

Interleukin (IL)-22 and IL-17 are coexpressed by Th17 cells and cooperatively enhance expression of antimicrobial peptides

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.150

IL-22 promotes fibroblast-mediated wound repair in the skin

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.150

STAT3 links IL-22 signaling in intestinal epithelial cells to mucosal wound healing

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.150

Increased serum interleukin 22 in patients with rheumatoid arthritis and correlation with disease activity

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.150

Endogenous IL-22 plays a dual role in arthritis: regulation of established arthritis via IFN-γ responses

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.150

Interleukin 22 serum levels are associated with radiographic progression in rheumatoid arthritis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.150

IL-22 and IL-20 are key mediators of the epidermal alterations in psoriasis while IL-17 and IFN-gamma are not.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.150

Innate and adaptive interleukin-22 protects mice from inflammatory bowel disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.150

IL-22BP is regulated by the inflammasome and modulates tumorigenesis in the intestine

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.150

Innate lymphoid cells sustain colon cancer through production of interleukin-22 in a mouse model

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.150

Expression of interleukin-22 in murine carcinoma cells did not influence tumour growth in vivo but did improve survival of the inoculated hosts

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.150

Type I interferon is selectively required by dendritic cells for immune rejection of tumors

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.150

Intratumoral T cell infiltration, MHC class I and STAT1 as biomarkers of good prognosis in colorectal cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.150

Modulation of antitumour immune responses by intratumoural Stat1 expression

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.150

Demonstration of an interferon gamma-dependent tumor surveillance system in immunocompetent mice

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.150

IFNgamma and lymphocytes prevent primary tumour development and shape tumour immunogenicity

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.150

Suppression of lymphoma and epithelial malignancies effected by interferon gamma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.150

Transcriptionally active Stat1 is required for the antiproliferative effects of both interferon alpha and interferon gamma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.150

Activation of the STAT signaling pathway can cause expression of caspase 1 and apoptosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.150

Cell growth arrest and induction of cyclin-dependent kinase inhibitor p21 WAF1/CIP1 mediated by STAT1.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.150

A critical function for type I interferons in cancer immunoediting

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.150

IFNgamma-dependent, spontaneous development of colorectal carcinomas in SOCS1-deficient mice

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.150

Stat1 and CD74 overexpression is co-dependent and linked to increased invasion and lymph node metastasis in triple-negative breast cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.150

Expression signature of IFN/STAT1 signaling genes predicts poor survival outcome in glioblastoma multiforme in a subtype-specific manner

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.150

The role of interferon in cancer therapy: a current perspective

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.150

Practical guidelines for the management of interferon-alpha-2b side effects in patients receiving adjuvant treatment for melanoma: expert opinion

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.150

Gene signature in melanoma associated with clinical activity: a potential clue to unlock cancer immunotherapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.150

IFN-gamma regulates the expression of B7-H1 in dermal fibroblast cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.150

Leptin signaling in breast cancer: An overview

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.150

Cross talk of signals between EGFR and IL-6R through JAK2/STAT3 mediate epithelial-mesenchymal transition in ovarian carcinomas.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.150

Mutations in the EGFR kinase domain mediate STAT3 activation via IL-6 production in human lung adenocarcinomas

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.150

31 March 2020

A renaissance for SRC

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.150

Prolactin promotes hepatocellular carcinoma through Janus kinase 2.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.150

STAT3 signaling: anticancer strategies and challenges.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.150

Signal Transduction and the Control of Gene Expression

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.150

Stats: transcriptional control and biological impact

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.150

Cytokine signaling in 2002: new surprises in the Jak/Stat pathway

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.150

G protein coupled receptor signaling through the Src and Stat3 pathway: role in proliferation and transformation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.150

Role of STATs as downstream signal transducers in Src family kinase-mediated tumorigenesis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.150

STATs in cancer inflammation and immunity: a leading role for STAT3

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.150

Stat3 activation is required for cellular transformation by v-src

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.150

Full oncogenic activities of v-Src are mediated by multiple signaling pathways. Ras as an essential mediator for cell survival.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.150

Stat3 activation by Src induces specific gene regulation and is required for cell transformation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.150

ErbB receptor-induced activation of stat transcription factors is mediated by Src tyrosine kinases

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.150

Src kinases mediate STAT growth pathways in squamous cell carcinoma of the head and neck

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.150

FLT3/ITD mutation signaling includes suppression of SHP-1.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.150

Biallelic mutation of SOCS-1 impairs JAK2 degradation and sustains phospho-JAK2 action in the MedB-1 mediastinal lymphoma line

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.150

Biallelic deletion within 16p13.13 including SOCS-1 in Karpas1106P mediastinal B-cell lymphoma line is associated with delayed degradation of JAK2 protein

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.150

Somatic mutations in PTPN11 in juvenile myelomonocytic leukemia, myelodysplastic syndromes and acute myeloid leukemia

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.150

DNA microarray analysis of stage progression mechanism in myelodysplastic syndrome

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.150

Multilevel dysregulation of STAT3 activation in anaplastic lymphoma kinase-positive T/null-cell lymphoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.150

Aberrant promoter methylation and loss of suppressor of cytokine signalling-1 gene expression in the development of uterine cervical carcinogenesis.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.150

Differential hypermethylation of SOCS genes in ovarian and breast carcinomas.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.150

Aberrant methylation of suppressor of cytokine signalling-1 (SOCS-1) gene in pancreatic ductal neoplasms

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.150

Hypermethylation-associated inactivation of the SOCS-1 gene, a JAK/STAT inhibitor, in human pancreatic cancers.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.150

Identification of novel epigenetically modified genes in human melanoma via promoter methylation gene profiling.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.150

Epigenetic inactivation of tumor suppressor genes in serum of patients with cutaneous melanoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.150

Combined hypermethylation and chromosome loss associated with inactivation of SSI-1/SOCS-1/JAB gene in human hepatocellular carcinomas

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.150

SOCS1 is a suppressor of liver fibrosis and hepatitis-induced carcinogenesis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.150

Reduced expression of SOCS2 and SOCS6 in hepatocellular carcinoma correlates with aggressive tumor progression and poor prognosis.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.150

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.150

IL-6-induced DNMT1 activity mediates SOCS3 promoter hypermethylation in ulcerative colitis-related colorectal cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.150

SOCS-3 is frequently silenced by hypermethylation and suppresses cell growth in human lung cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.150

SOCS3 promoter methylation is mutually exclusive to EGFR amplification in gliomas and promotes glioma cell invasion through STAT3 and FAK activation.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.150

Prognostic relevance of SOCS3 hypermethylation in patients with glioblastoma multiforme.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.150

Epigenetic silencing of SOCS3 identifies a subset of prostate cancer with an aggressive behavior

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.150

SOCS, inflammation, and cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.150

The role of suppressors of cytokine signalling in human neoplasms

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.150

Aberrant methylation of SOCS-1 was observed in younger colorectal cancer patients.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.150

Identification of SOCS2 and SOCS6 as biomarkers in human colorectal cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.150

Epigenetic inactivation of SOCS-1 by CpG island hypermethylation in human gastric carcinoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.150

Methylation of SOCS-3 and SOCS-1 in the carcinogenesis of Barrett's adenocarcinoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.150

IL-6 triggers malignant features in mammospheres from human ductal breast carcinoma and normal mammary gland

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.150

Fibroblasts isolated from common sites of breast cancer metastasis enhance cancer cell growth rates and invasiveness in an interleukin-6-dependent manner.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.150

Interleukin 6 secreted from adipose stromal cells promotes migration and invasion of breast cancer cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.150

Signal transducer and activator of transcription 3 is required for hypoxia-inducible factor-1alpha RNA expression in both tumor cells and tumor-associated myeloid cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.150

Constitutive Stat3 activity up-regulates VEGF expression and tumor angiogenesis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.150

Targeting Stat3 blocks both HIF-1 and VEGF expression induced by multiple oncogenic growth signaling pathways

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.150

IL-23 promotes tumour incidence and growth

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.150

IL-17 can promote tumor growth through an IL-6-Stat3 signaling pathway

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.150

IL-27 suppresses RANKL expression in CD4+ T cells in part through STAT3

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.150

PD-L1 expression on tolerogenic APCs is controlled by STAT-3.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.150

Group 3 innate lymphoid cells inhibit T-cell-mediated intestinal inflammation through aryl hydrocarbon receptor signaling and regulation of microflora.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.150

Innate lymphoid cells promote anatomical containment of lymphoid-resident commensal bacteria.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.150

Lymphotoxin regulates commensal responses to enable diet-induced obesity

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.150

IL-22 deficiency alters colonic microbiota to be transmissible and colitogenic.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.150

The cytokine IL-22 promotes pathogen colonization by suppressing related commensal bacteria.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.150

Inhibition of constitutively active Stat3 suppresses proliferation and induces apoptosis in glioblastoma multiforme cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.150

Opposing actions of STAT-1 and STAT-3 on the Bcl-2 and Bcl-x promoters.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.150

Stat3-mediated Myc expression is required for Src transformation and PDGF-induced mitogenesis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.150

Stat3: linking inflammation to epithelial cancer - more than a "gut" feeling?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.150

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.150

Interleukin-6 induces an epithelial-mesenchymal transition phenotype in human breast cancer cells.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.150

IL-6 promotes head and neck tumor metastasis by inducing epithelial-mesenchymal transition via the JAK-STAT3-SNAIL signaling pathway

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.150

A long noncoding RNA activated by TGF-β promotes the invasion-metastasis cascade in hepatocellular carcinoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.150

Transcription factor signal transducer and activator of transcription 5 promotes growth of human prostate cancer cells in vivo

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.150

Signal transducer and activator of transcription 5A/B in prostate and breast cancers

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.150

Therapeutic inhibition of Jak activity inhibits progression of gastrointestinal tumors in mice.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.150

Chemokines integrate JAK/STAT and G‐protein pathways during chemotaxis and calcium flux responses

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.150

Phospho-STAT5 expression is associated with poor prognosis of human colonic adenocarcinoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.150

Activation of signal transducer and activator of transcription 5 in human prostate cancer is associated with high histological grade

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.150

Signal transducers and activators of transcription 5b activation enhances hepatocellular carcinoma aggressiveness through induction of epithelial-mesenchymal transition.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.150

Endothelial CCR2 signaling induced by colon carcinoma cells enables extravasation via the JAK2-Stat5 and p38MAPK pathway

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.150

Inhibition of STAT5 induces G1 cell cycle arrest and reduces tumor cell invasion in human colorectal cancer cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.150

Signal transducer and activator of transcription-5 activation and breast cancer prognosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.150

Disruption of the growth hormone--signal transducer and activator of transcription 5--insulinlike growth factor 1 axis severely aggravates liver fibrosis in a mouse model of cholestasis.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.150

Loss of STAT5 causes liver fibrosis and cancer development through increased TGF-{beta} and STAT3 activation.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.150

A STAT3-mediated metabolic switch is involved in tumour transformation and STAT3 addiction.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.150

Understanding the Warburg effect: the metabolic requirements of cell proliferation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.150

Function of mitochondrial Stat3 in cellular respiration

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.150

Mitochondrial STAT3 supports Ras-dependent oncogenic transformation.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.150

The MEK-ERK pathway is necessary for serine phosphorylation of mitochondrial STAT3 and Ras-mediated transformation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.150

Mitochondrial translocation of signal transducer and activator of transcription 5 (STAT5) in leukemic T cells and cytokine-stimulated cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.150

Stem cell marker (Nanog) and Stat-3 signaling promote MicroRNA-21 expression and chemoresistance in hyaluronan/CD44-activated head and neck squamous cell carcinoma cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.150

ER re-expression and re-sensitization to endocrine therapies in ER-negative breast cancers

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.150

Estrogen receptor-alpha methylation predicts melanoma progression

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.150

Disruption of STAT3 signalling promotes KRAS-induced lung tumorigenesis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.150

p19(ARF) /p14(ARF) controls oncogenic functions of signal transducer and activator of transcription 3 in hepatocellular carcinoma.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.150

Stat3 is a negative regulator of intestinal tumor progression in Apc(Min) mice

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.150

Drosophila intestinal response to bacterial infection: activation of host defense and stem cell proliferation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.150

Cytokine/Jak/Stat signaling mediates regeneration and homeostasis in the Drosophila midgut

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.150

JAK/STAT signaling coordinates stem cell proliferation and multilineage differentiation in the Drosophila intestinal stem cell lineage.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.150

EGF signaling regulates the proliferation of intestinal stem cells in Drosophila

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.150

Non-autonomous crosstalk between the Jak/Stat and Egfr pathways mediates Apc1-driven intestinal stem cell hyperplasia in the Drosophila adult midgut.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.150

The Hippo tumor suppressor pathway regulates intestinal stem cell regeneration

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.150

Interleukin-11 protects the clonogenic stem cells in murine small-intestinal crypts from impairment of their reproductive capacity by radiation.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.150

Protection of the small intestinal clonogenic stem cells from radiation-induced damage by pretreatment with interleukin 11 also increases murine survival time

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.150

Signaling pathways associated with colonic mucosa hyperproliferation in mice overexpressing gastrin precursors.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.150

Comprehensive molecular characterization of gastric adenocarcinoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.150

Interleukin-6 and cachexia in ApcMin/+ mice

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.150

TGF-beta suppresses tumor progression in colon cancer by inhibition of IL-6 trans-signaling.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.150

IL-6 and Stat3 are required for survival of intestinal epithelial cells and development of colitis-associated cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.150

Therapeutic efficacy of CEP-33779, a novel selective JAK2 inhibitor, in a mouse model of colitis-induced colorectal cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.150

gp130-mediated Stat3 activation in enterocytes regulates cell survival and cell-cycle progression during colitis-associated tumorigenesis.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.150

Inhibition of the JAK2/STAT3 pathway reduces gastric cancer growth in vitro and in vivo

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.150

Partial inhibition of gp130-Jak-Stat3 signaling prevents Wnt-β-catenin-mediated intestinal tumor growth and regeneration.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.150

Gender disparity in liver cancer due to sex differences in MyD88-dependent IL-6 production

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.150

Frequent in-frame somatic deletions activate gp130 in inflammatory hepatocellular tumours

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.150

Somatic mutations activating STAT3 in human inflammatory hepatocellular adenomas

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.150

Biochemical and functional analyses of gp130 mutants unveil JAK1 as a novel therapeutic target in human inflammatory hepatocellular adenoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.150

Jak inhibitor induces S phase cell-cycle arrest and augments TRAIL-induced apoptosis in human hepatocellular carcinoma cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.150

Development of a novel azaspirane that targets the Janus kinase-signal transducer and activator of transcription (STAT) pathway in hepatocellular carcinoma in vitro and in vivo

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.150

Growth arrest and DNA damage 45G down-regulation contributes to Janus kinase/signal transducer and activator of transcription 3 activation and cellular senescence evasion in hepatocellular carcinoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.150

Autocrine IL-6 signaling: a key event in tumorigenesis?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.150

IL-6 promotes malignant growth of skin SCCs by regulating a network of autocrine and paracrine cytokines

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.150

Whole-genome sequencing identifies recurrent mutations in hepatocellular carcinoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.150

SHP2 is overexpressed and inhibits pSTAT1-mediated APM component expression, T-cell attracting chemokine secretion, and CTL recognition in head and neck cancer cells.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.150

Requirement of Stat3 but not Stat1 activation for epidermal growth factor receptor- mediated cell growth In vitro

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.150

Constitutive activation of Stat3 signaling abrogates apoptosis in squamous cell carcinogenesis in vivo

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.150

Crosstalk between cancer and immune cells: role of STAT3 in the tumour microenvironment.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.150

Photochemical preparation of a pyridone containing tetracycle: a Jak protein kinase inhibitor

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.150

The structural basis of Janus kinase 2 inhibition by a potent and specific pan-Janus kinase inhibitor

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.150

Modulation of Activation-Loop Phosphorylation by JAK Inhibitors Is Binding Mode Dependent

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.150

Safety and efficacy of CYT387, a JAK1 and JAK2 inhibitor, in myelofibrosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.150

AZD1480: a phase I study of a novel JAK2 inhibitor in solid tumors

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.150

Tofacitinib or Adalimumab versus Placebo in Rheumatoid Arthritis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.150

Selective JAK inhibitors in development for rheumatoid arthritis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.150

Jak1 has a dominant role over Jak3 in signal transduction through γc-containing cytokine receptors

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.150

Selective inhibitors of the Janus kinase Jak3--Are they effective?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.150

SOCS3 binds specific receptor–JAK complexes to control cytokine signaling by direct kinase inhibition

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.150

Heat shock protein 90 inhibitor is synergistic with JAK2 inhibitor and overcomes resistance to JAK2-TKI in human myeloproliferative neoplasm cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.150

The novel JAK inhibitor CYT387 suppresses multiple signalling pathways, prevents proliferation and induces apoptosis in phenotypically diverse myeloma cells.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.150

The JAK inhibitor AZD1480 regulates proliferation and immunity in Hodgkin lymphoma.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.150

The oral HDAC inhibitor pracinostat (SB939) is efficacious and synergistic with the JAK2 inhibitor pacritinib (SB1518) in preclinical models of AML.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.150

Cotreatment with panobinostat and JAK2 inhibitor TG101209 attenuates JAK2V617F levels and signaling and exerts synergistic cytotoxic effects against human myeloproliferative neoplastic cells.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.150

JAK1/2 and Pan-deacetylase inhibitor combination therapy yields improved efficacy in preclinical mouse models of JAK2V617F-driven disease.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.150

Dual PI3K/AKT/mTOR inhibitor BEZ235 synergistically enhances the activity of JAK2 inhibitor against cultured and primary human myeloproliferative neoplasm cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.150

Induction of myeloproliferative disorder and myelofibrosis by thrombopoietin receptor W515 mutants is mediated by cytosolic tyrosine 112 of the receptor.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.150

Combination treatment for myeloproliferative neoplasms using JAK and pan-class I PI3K inhibitors

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.150

Constitutive activation of Stat5 promotes its cytoplasmic localization and association with PI3-kinase in myeloid leukemias

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.150

Apoptosis induced by JAK2 inhibition is mediated by Bim and enhanced by the BH3 mimetic ABT-737 in JAK2 mutant human erythroid cells.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.150

Combination of AG490, a Jak2 inhibitor, and methylsulfonylmethane synergistically suppresses bladder tumor growth via the Jak2/STAT3 pathway.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.150

P-glycoprotein (MDR1/ABCB1) and breast cancer resistance protein (BCRP/ABCG2) restrict brain accumulation of the JAK1/2 inhibitor, CYT387.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.150

Heterodimeric JAK-STAT activation as a mechanism of persistence to JAK2 inhibitor therapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.150

LLL-3, a STAT3 inhibitor, represses BCR-ABL-positive cell proliferation, activates apoptosis and improves the effects of Imatinib mesylate.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.150

Drosophila C-terminal Src kinase negatively regulates organ growth and cell proliferation through inhibition of the Src, Jun N-terminal kinase, and STAT pathways.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.150

Random mutagenesis reveals residues of JAK2 critical in evading inhibition by a tyrosine kinase inhibitor

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.150

Inactivation of SSI-1, a JAK/STAT inhibitor, in human hepatocellular carcinomas, as revealed by two-dimensional electrophoresis.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.150

Hypermethylation associated with inactivation of the SOCS-1 gene, a JAK/STAT inhibitor, in human hepatoblastomas

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.150

ADAM17-dependent c-MET-STAT3 signaling mediates resistance to MEK inhibitors in KRAS mutant colorectal cancer.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.150

Drug resistance via feedback activation of Stat3 in oncogene-addicted cancer cells.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.150

The role of Stat5 transcription factors as tumor suppressors or oncogenes

31 March 2020

1 reference

12 December 2020

Interleukin 10 production by human melanoma

1 reference

12 December 2020

Constitutive activation of Stat5b contributes to carcinogenesis in vivo

1 reference

12 December 2020

SOCS-1, a negative regulator of the JAK/STAT pathway, is silenced by methylation in human hepatocellular carcinoma and shows growth-suppression activity

1 reference

12 December 2020

tyk2, prototype of a novel class of non-receptor tyrosine kinase genes

1 reference

12 December 2020

CD147 promotes Src-dependent activation of Rac1 signaling through STAT3/DOCK8 during the motility of hepatocellular carcinoma cells

1 reference

12 December 2020

Novel roles of unphosphorylated STAT3 in oncogenesis and transcriptional regulation

1 reference

12 December 2020

Interleukin-11: a multifunctional growth factor derived from the hematopoietic microenvironment

1 reference

12 December 2020

STAT3 and STAT1 mediate IL-11-dependent and inflammation-associated gastric tumorigenesis in gp130 receptor mutant mice.

1 reference

12 December 2020

Signal transducers and activators of transcription 5B potentiates v-Src-mediated transformation of NIH-3T3 cells

1 reference

12 December 2020

Mammary epithelial reconstitution with gene-modified stem cells assigns roles to Stat5 in luminal alveolar cell fate decisions, differentiation, involution, and mammary tumor formation

1 reference

12 December 2020

IL-22 ameliorates intestinal inflammation in a mouse model of ulcerative colitis

1 reference

12 December 2020

Methylation-mediated silencing of SOCS-1 gene in hepatocellular carcinoma derived from cirrhosis

1 reference

12 December 2020

Human non-small cell lung cancer cells express a type 2 cytokine pattern.

1 reference

12 December 2020

Interleukin-11 prevents apoptosis and accelerates recovery of small intestinal mucosa in mice treated with combined chemotherapy and radiation

1 reference

12 December 2020

Constitutive activation of signal transducers and activators of transcription 3 correlates with cyclin D1 overexpression and may provide a novel prognostic marker in head and neck squamous cell carcinoma.

1 reference

12 December 2020

A bone marrow stromal-derived growth factor, interleukin-11, stimulates recovery of small intestinal mucosal cells after cytoablative therapy

1 reference

12 December 2020

Elevated serum levels of interleukin-10 in patients with metastatic malignant melanoma

1 reference

12 December 2020

Resident enteric bacteria are necessary for development of spontaneous colitis and immune system activation in interleukin-10-deficient mice

1 reference

12 December 2020

c-Src, receptor tyrosine kinases, and human cancer

1 reference

12 December 2020

IL-10 production in cutaneous basal and squamous cell carcinomas. A mechanism for evading the local T cell immune response

1 reference

12 December 2020